AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22693238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF) 3 mg/kg body mass
Number of subjects: 10
Study 22693238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB) 0.3 g · kg⁻¹ · BM⁻¹
Number of subjects: 10
Study 22693238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Sodium Bicarbonate (CAFF+SB)
Number of subjects: 10
Study 22693238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 10
Study 20022589 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (single course)
Number of subjects: 183
Study 18332706 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 2.5-3.0 g/kg/day
Number of subjects: 0
Study 18332706 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 4.0 g/kg/day
Number of subjects: 0
Study 16260639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Number of subjects: 60
Study 16260639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 60
Study 16260639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg
Number of subjects: 60
Study 12163796 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position for 6 hours for four consecutive days
Number of subjects: 16
Study 12163796 — intervention group
Group type: COMPARATOR
Intervention: Nonprone position
Number of subjects: 16
Study 10381666 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (starting doses of 60-1000 mg per day, reduced to 40-50 mg per day after 4-6 weeks)
Number of subjects: 22
Study 10381666 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (conventional dose 60-80 mg per day vs very high doses 200-1000 mg per day)
Number of subjects: 22
Study 10381666 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (various doses)
Number of subjects: 22
Study 7594326 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg and AMPC 1,500 mg
Number of subjects: 40
Study 7594326 — intervention group
Group type: COMPARATOR
Intervention: LPZ 30 mg alone
Number of subjects: 40
Study 2407766 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (25 mmol)
Number of subjects: 0
Study 2407766 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (25 mmol)
Number of subjects: 0
Study 120339 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCA (160 mg/extraction site)
Number of subjects: 120
Study 120339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 120339 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCA
Number of subjects: 120
Study 31280035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with medication
Number of subjects: 124
Study 31280035 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 124
Study 31280035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 124
Study 28043048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IFG-IGT
Number of subjects: 7542
Study 28043048 — intervention group
Group type: COMPARATOR
Intervention: Isolated IFG
Number of subjects: 7542
Study 28043048 — intervention group
Group type: COMPARATOR
Intervention: Isolated IGT
Number of subjects: 7542
Study 28043048 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, urban residence, family history of diabetes, smoking status, abdominal obesity, hypertension, high triglycerides, low HDL cholesterols
Number of subjects: 7542
Study 26410589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) for 20 days
Number of subjects: 32
Study 26410589 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet (MD) for 20 days
Number of subjects: 32
Study 23224592 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental state anxiety
Number of subjects: 30
Study 23224592 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental trait anxiety
Number of subjects: 30
Study 23224592 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental trait anxiety in treatment responders
Number of subjects: 30
Study 21246185 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30% total energy, n = 53)
Number of subjects: 99
Study 21246185 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (55% total energy, n = 46)
Number of subjects: 99
Study 18471454 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S) 1,000/20 mg/day
Number of subjects: 319
Study 18471454 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S) 2,000/20 mg/day
Number of subjects: 319
Study 18471454 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day
Number of subjects: 319
Study 18471454 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended release plus simvastatin (NER/S)
Number of subjects: 319
Study 16936391 — intervention group
Group type: COMPARATOR
Intervention: Splinting (wearing splint in neutral position for 4 weeks)
Number of subjects: 40
Study 16936391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 20 mg/day for 2 weeks followed by 10 mg/day for 2 weeks
Number of subjects: 40
Study 14657842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihistamines
Number of subjects: 0
Study 10690544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment NSE levels
Number of subjects: 121
Study 10690544 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced minimum NSE values
Number of subjects: 121
Study 10690544 — intervention group
Group type: COMPARATOR
Intervention: Etoposide and cisplatin treatment (4 to 6 cycles)
Number of subjects: 121
Study 9088679 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 50
Study 9088679 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 50
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 5 micrograms/h
Number of subjects: 18
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 20 micrograms/h
Number of subjects: 18
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 80 micrograms/h
Number of subjects: 18
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 5 micrograms/h with secretin and ceruletide
Number of subjects: 18
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 20 micrograms/h with secretin and ceruletide
Number of subjects: 18
Study 1371938 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 80 micrograms/h with secretin and ceruletide
Number of subjects: 18
Study 3884406 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg 3 times daily orally)
Number of subjects: 25
Study 3884406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3884406 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide and Placebo
Number of subjects: 25
Study 29540420 — intervention group
Group type: EXPERIMENTAL
Intervention: New Orleans intervention model (NIM) - an infant mental health service
Number of subjects: 0
Study 29540420 — intervention group
Group type: COMPARATOR
Intervention: Case management (CM) - enhanced social work services as usual
Number of subjects: 0
Study 27094495 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization group (manual therapy and neurodynamic techniques)
Number of subjects: 0
Study 27094495 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysical modalities group (red and infrared laser and ultrasound therapy)
Number of subjects: 0
Study 24428467 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg orally once daily) plus sofosbuvir (400 mg orally once daily) for 12 or 24 weeks, with or without ribavirin
Number of subjects: 211
Study 24428467 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus sofosbuvir (with or without ribavirin)
Number of subjects: 211
Study 22856376 — intervention group
Group type: COMPARATOR
Intervention: Brain training intervention over a 30-day period
Number of subjects: 1500
Study 22856376 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI testing
Number of subjects: 1500
Study 19847185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 0
Study 19847185 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 0
Study 18408224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + reduced-dose interferon (IFN) 6 or 3 MIU
Number of subjects: 649
Study 18408224 — intervention group
Group type: COMPARATOR
Intervention: IFN + placebo
Number of subjects: 649
Study 18408224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + reduced-dose IFN
Number of subjects: 649
Study 16455029 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 38
Study 16455029 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 38
Study 16455029 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 38
Study 16455029 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphy
Number of subjects: 38
Study 16455029 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 38
Study 12354701 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial gradient present (Group 1)
Number of subjects: 228
Study 12354701 — intervention group
Group type: COMPARATOR
Intervention: No brachial gradient (Group 2)
Number of subjects: 228
Study 11279947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg per day
Number of subjects: 52
Study 11279947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8826574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administration
Number of subjects: 0
Study 8826574 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1874262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (RP)
Number of subjects: 182
Study 1874262 — intervention group
Group type: COMPARATOR
Intervention: Counselling programme (CP)
Number of subjects: 182
Study 1874262 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 182
Study 1874262 — intervention group
Group type: COMPARATOR
Intervention: Combined UC and CP
Number of subjects: 182
Study 6617242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide + methyldopa (average 1100 mg daily)
Number of subjects: 29
Study 6617242 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide + methyldopa (average 1575 mg daily)
Number of subjects: 29
Study 6617242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide (Step 1 medication only)
Number of subjects: 29
Study 6617242 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg indapamide (Step 1) and 50 mg hydrochlorothiazide (Step 1)
Number of subjects: 29
Study 30919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental perceptions of child weight status
Number of subjects: 331
Study 30919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of overweight children
Number of subjects: 331
Study 30919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Feeding Questionnaire (CFQ) scores
Number of subjects: 331
Study 31806127 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylactic antibiotic treatment
Number of subjects: 19603
Study 31806127 — intervention group
Group type: COMPARATOR
Intervention: Incremental prophylactic antibiotic treatment
Number of subjects: 19603
Study 31806127 — intervention group
Group type: EXPERIMENTAL
Intervention: PADIT risk score (0 to 15 points)
Number of subjects: 19603
Study 29251978 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized recommendations (CR) during Recovery Line calls
Number of subjects: 127
Study 29251978 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame and loss-frame reminder messages
Number of subjects: 127
Study 29251978 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, immediate, and long-term message latency
Number of subjects: 127
Study 29251978 — intervention group
Group type: COMPARATOR
Intervention: No recommendations on Recovery Line calls (Control)
Number of subjects: 127
Study 26590381 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional monofilament sutures (Group 1)
Number of subjects: 142
Study 26590381 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed knotless sutures (Group 2)
Number of subjects: 142
Study 23990660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of hypertension
Number of subjects: 0
Study 22315048 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (80 mg caffeine)
Number of subjects: 24
Study 22315048 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 24
Study 17161119 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 90 μg/ethinyl estradiol 20 μg daily for 1 year
Number of subjects: 146
Study 15753500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast group (1 mL/sec)
Number of subjects: 40
Study 15753500 — intervention group
Group type: COMPARATOR
Intervention: Slow group (0.05 mL/sec)
Number of subjects: 40
Study 12224975 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm pulsed-dye laser (PDL) (5 J/cm(2))
Number of subjects: 10
Study 12224975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC) (20 mg/mL)
Number of subjects: 10
Study 12224975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) (50 mg/mL)
Number of subjects: 10
Study 12224975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional TAC (1 mg/mL) mixed with 5-FU (45 mg/mL)
Number of subjects: 10
Study 12224975 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10
Study 9690971 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antipsychotic drugs (clozapine, risperidone, olanzapine, amisulpride, quetiapine, sertindole)
Number of subjects: 0
Study 9690971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 9690971 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs (haloperidol, chlorpromazine)
Number of subjects: 0
Study 7750167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 7750167 — intervention group
Group type: COMPARATOR
Intervention: Chinese and western medicine treatments
Number of subjects: 0
Study 3383542 — intervention group
Group type: EXPERIMENTAL
Intervention: minibag via gravity flow (MG)
Number of subjects: 11
Study 3383542 — intervention group
Group type: EXPERIMENTAL
Intervention: minibag with secondary infusion tubing below a volumetric infusion pump (MP)
Number of subjects: 11
Study 3383542 — intervention group
Group type: EXPERIMENTAL
Intervention: metered chamber via volumetric infusion pump (MC)
Number of subjects: 11
Study 3383542 — intervention group
Group type: EXPERIMENTAL
Intervention: syringe pump (SP)
Number of subjects: 11
Study 31626568 — intervention group
Group type: COMPARATOR
Intervention: Action Observation (AO)
Number of subjects: 45
Study 31626568 — intervention group
Group type: COMPARATOR
Intervention: Motor Imagery (MI)
Number of subjects: 45
Study 31626568 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study 29573038 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM)
Number of subjects: 29
Study 29573038 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful Cutaneous Electrical Stimulation (PCES) with constant current intensity
Number of subjects: 29
Study 29573038 — intervention group
Group type: COMPARATOR
Intervention: Painful Cutaneous Electrical Stimulation (PCES) with variable intensities
Number of subjects: 29
Study 28830365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate infusion (25 ml/kg, approximately 2 l over 30 min)
Number of subjects: 7
Study 23952181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriatic drops (tropicamide 0.5% and phenylephrine 2.5%)
Number of subjects: 0
Study 23952181 — intervention group
Group type: COMPARATOR
Intervention: Control group (undilated pupils)
Number of subjects: 0
Study 23952181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated pupils (with glaucoma)
Number of subjects: 0
Study 23952181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated pupils (without glaucoma)
Number of subjects: 0
Study 23325710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide (TA)
Number of subjects: 40
Study 23325710 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinse of triamcinolone acetonide (TA)
Number of subjects: 40
Study 21830063 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (5-7.5 mg bid) plus bisoprolol 5 mg od
Number of subjects: 29
Study 21830063 — intervention group
Group type: COMPARATOR
Intervention: bisoprolol uptitrated to 7.5 mg and then 10 mg od
Number of subjects: 29
Study 18330518 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-panel volumetric CT (VCT)
Number of subjects: 22
Study 18330518 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT (cCT)
Number of subjects: 22
Study 17126776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (3-in, 7.5 cm)
Number of subjects: 60
Study 17126776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3-in, 7.5 cm)
Number of subjects: 60
Study 14506196 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I-trace-labeled BsMAb doses escalated from 10 to 100 mg/m(2)
Number of subjects: 35
Study 14506196 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/m(2) BsMAb and 2.6-4.2 GBq of (131)I-hapten
Number of subjects: 35
Study 14506196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of BsMAb dose to 40 mg/m(2)
Number of subjects: 35
Study 14506196 — intervention group
Group type: COMPARATOR
Intervention: (131)I-hapten
Number of subjects: 35
Study 11374263 — intervention group
Group type: EXPERIMENTAL
Intervention: Full weight-bearing immediately after operation (Group A)
Number of subjects: 33
Study 11374263 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing after 6 weeks (Group B)
Number of subjects: 33
Study 9916607 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg BID for 3 months
Number of subjects: 178
Study 9916607 — intervention group
Group type: COMPARATOR
Intervention: Theophylline BID for 3 months
Number of subjects: 178
Study 7914795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 40-2148 (400 mg diluted in 100 ml water, twice a day for 14 days)
Number of subjects: 12
Study 7914795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3196390 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium 25 mg/kg p.o.
Number of subjects: 0
Study 3196390 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium 50 mg/kg p.o.
Number of subjects: 0
Study 3196390 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium 100 mg/kg p.o.
Number of subjects: 0
Study 3196390 — intervention group
Group type: COMPARATOR
Intervention: Emepronium 200 mg q.i.d. in human volunteers
Number of subjects: 0
Study 3196390 — intervention group
Group type: COMPARATOR
Intervention: Emepronium 400 mg q.i.d. in human volunteers
Number of subjects: 0
Study 31301812 — intervention group
Group type: EXPERIMENTAL
Intervention: Malawi Trauma Score (MTS)
Number of subjects: 62354
Study 28091393 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)
Number of subjects: 717
Study 28091393 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)
Number of subjects: 717
Study 28091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 717
Study 25272149 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-enriched n-3 1000 mg/d
Number of subjects: 196
Study 25272149 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched n-3 1000 mg/d
Number of subjects: 196
Study 25272149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 24235221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% Ca from HSC
Number of subjects: 240
Study 24235221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% Ca with phytase
Number of subjects: 240
Study 24235221 — intervention group
Group type: EXPERIMENTAL
Intervention: HSC
Number of subjects: 240
Study 24235221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% Ca
Number of subjects: 240
Study 21794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based education and activation
Number of subjects: 0
Study 21794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program developed by Aviva Canada
Number of subjects: 0
Study 21794155 — intervention group
Group type: COMPARATOR
Intervention: Legislated standard of care (Pre-approved Framework Guideline for Whiplash)
Number of subjects: 0
Study 19114888 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG-enriched immune-enhancing diet (IED)
Number of subjects: 22
Study 19114888 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control group, n = 11)
Number of subjects: 22
Study 16934909 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-15 200 mg/m2/week with docetaxel 35 mg/m2/week (Arm A)
Number of subjects: 62
Study 16934909 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 35 mg/m2/week alone (Arm B)
Number of subjects: 62
Study 16934909 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) analyses
Number of subjects: 62
Study 15293486 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint protection programme (educational-behavioural training)
Number of subjects: 127
Study 11737115 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided biopsy (GI)
Number of subjects: 82
Study 11737115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided biopsy (GII)
Number of subjects: 82
Study 9266922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg of iron sucrose)
Number of subjects: 7
Study 9266922 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (r‐HuEPO; 300 U/kg body weight) alone
Number of subjects: 7